Professor Georgina V Long AO
gvlongphdmd.bsky.social
Professor Georgina V Long AO
@gvlongphdmd.bsky.social
Medical Oncologist & Immunotherapist, Clinical Trialist, Cancer Drug Developer, Translational Researcher University of Sydney, Medical Director Melanoma Institute Australia, Joint Australian of Year 2024, Fulbright Alumnus, Fellow AAS & AAHMS
Join me & MIA multidisciplinary experts at Neoadjuvant Treatment Symposium, to help clinicians navigate the evolving treatment landscape for #melanoma, after recent PBS listing for #neoadjuvant regimens. Mon evening 24 Nov AEDT in person in Sydney, or online. events.humanitix.com/neoadjuvant-...
Neoadjuvant treatment in 2025
Advance your expertise in neoadjuvant therapy and melanoma care at our upcoming symposium for multidisciplinary specialists.
events.humanitix.com
October 29, 2025 at 12:41 PM

INNOVATE Naples - Paolo Ascierto hosts clinician/researchers discussing #CANCER #NEOADJUVANT #immunotherapy. Favorite meeting for patient-centered novel trials. Discussed optimising immunotherapy across multiple cancers & #melanoma to cure more Grazie tutti!
July 12, 2025 at 5:43 PM
Important week - #UnitedNation international #women’s day week! Honoured to speak about courage, unconscious bias, inspiration, and my 5 best pieces advice 4 action & change. #ING #marieclaire #NSWeducation #RoyalSocietyNSW @sydneyuni.bsky.social @melanomaau.bsky.social
March 9, 2025 at 2:59 AM
So proud of this aussie trial - changed practice. @melanomaau.bsky.social @sydneyuni.bsky.social
@science.org.au
Ipilimumab + nivolumab vs nivolumab in patients with #melanoma brain metastases (ABC): 7-yr follow-up of randomised, ph 2 study - The Lancet Oncology www.thelancet.com/journals/lan...
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Our findings suggest that ipilimumab plus nivolumab maintains efficacy to at least 7 years in patients with active asymptomatic brain metastasis. Upfront ipilimumab plus nivolumab should be the standa...
www.thelancet.com
February 18, 2025 at 12:28 PM
Welcome ‘25 @melanomaau.bsky.social fellows. Ciao fab Drs fr 2024 Ruby, Bec & Andea, work with top #clinicaltrials team & advance practice #nurses. Togeth we deliver #cancer care, keep patients SAFE & push boundaries - 0 deaths fr #melanoma. ❤️ Working to make a difference-Highlight of my work week.
February 8, 2025 at 3:06 AM
Celebrating #australianoftheyear 2025 with my kids (1 in USA), my rock of a husband&my wise Mum. Lost Dad in 2024 ❤️ but made pioneering #melanoma research & transformed clinical practice, groundbreaking science with brilliant women, exploring Australia & #changemakers.

youtu.be/VfJKuE114Do?...
February 1, 2025 at 10:33 AM
What an amazing group of 2025 Australians of the Year! Tears flowed freely as their stories were told - Neale #fightnmd, Olly #wheelchairs for kids, Katrina #QUT and Vanessa & Hannah #cafesteppingstone. Making #Australia a better place! @sydneyuni.bsky.social @melanomaau.bsky.social #AOTY
January 29, 2025 at 12:37 PM